---
title: semaglutide
popular_name: "Semaglutide"
developmental_codes: ["Semaglutide", "GLP-1 agonist"]
street_names: ["Semaglutide", "Ozempic", "Wegovy"]
product_names: ["Ozempic", "Wegovy", "Rybelsus"]
description: Semaglutide is an anti-diabetic medication used for the treatment of typeÂ 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis.
short_description: "GLP-1 agonist for type 2 diabetes and weight management (Ozempic/Wegovy) with cardiovascular benefits and significant weight loss effects."
benefits: ["Significant weight loss and appetite suppression", "Improved blood sugar control", "Reduced cardiovascular risk", "Enhanced insulin sensitivity", "Decreased food cravings", "Improved metabolic health", "Potential neuroprotective effects", "Aids in fat loss and metabolism"]
dosage_levels: ["Starting dose: 0.25mg weekly (subcutaneous)", "Titration: 0.5mg weekly after 4 weeks", "Maintenance: 1mg weekly (weight loss)", "Maximum: 2.4mg weekly for enhanced weight loss"]
research: ["wikipedia: https://en.wikipedia.org/wiki/semaglutide", "pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide", "clinical trials: https://clinicaltrials.gov/search?term=semaglutide", "pubmed study: https://pubmed.ncbi.nlm.nih.gov/41105066/", "pubmed study: https://pubmed.ncbi.nlm.nih.gov/41104517/"]
tags: ["fat loss", "subcutaneous"]
affiliate_links: []
is_natty: false
created_at: 2025-10-17T08:26:21.285Z
last_updated_at: 2025-10-18T05:18:24.818Z
---